The FDA has approved Steqeyma, a biosimilar of J&J's Stelara, for the treatment of Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis. Read more here.

Seeking Alpha

United States

FDA approves Celltrion's biosimilar of J&J's Stelara (JNJ:NYSE)

Media Bias/Fact Check

STEQEYMA (CT-P43) is approved for both adult and pediatric patients with plaque psoriasis (PsO) and active psoriatic arthritis (PsA) as well as adults with Crohn’s disease (CD) and ulcerative colitis (UC) STEQEYMA is a strategic addition to Celltrion’s portfolio, expanding the portfolio and building on Celltrion’s expertise in immunology STEQEYMA is expected to be marketed in the U.S. in February 2025  JERSEY CITY, NJ, USA I December 17, 2024 I …

pipelinereview

U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) - Pipelinereview

STEQEYMA (CT-P43) is approved for both adult and pediatric patients with plaque psoriasis (PsO) and active psoriatic arthritis (PsA) as well as adults with Crohn’s disease (CD) and ulcerative colitis (UC) STEQEYMA is a strategic addition to Celltrion’s portfolio, expanding the portfolio and building on Celltrion’s expertise in immunology  STEQEYMA is expected to be marketed in the U.S. in February 2025  JERSEY CITY, N.J., Dec. 17, 2024 /PRNewswi…

pressreach.com

U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) - PressReach

Ustekinumab-stba (Steqeyma; Celltrion) is a subcutaneous treatment for adult and pediatric patients with plaque psoriasis arthritis, psoriatic arthritis, Crohn disease, and ulcerative colitis.

Pharmacy Times

Ustekinumab-stba Receives FDA Approval for Autoimmune Disorder and Inflammatory Bowel Disease

Celltrion’s CT-P43/ustekinumab-stba has been approved under the name Steqeyma and is expected to launch in February 2025.

hcplive.com

FDA Approves Seventh Ustekinumab Biosimilar

Originally approved in 2009, Stelara patents began expiring in 2023, leading to an influx of recent biosimilars.

Managed Healthcare Executive

FDA Approves Seventh Stelara Biosimilar, Steqeyma

The FDA approved Celltrion's Steqeyma (ustekinumab-stba), making it the seventh biosimilar slated to compete against blockbuster Stelara (reference ustekinumab) in 2025.

FDA approves Celltrion's biosimilar of J&J's Stelara (JNJ:NYSE)

Coverage Details

Give the gift of Perspective

Bias Distribution

Ownership

Similar News Topics

Similar News Topics